Latest Production News

5E Advanced Materials reports Q3 2025 results highlighting operational progress with specialty glass trials and updated capital estimates, alongside a major debt restructuring and reverse stock split. Despite improved liquidity, the company faces ongoing going concern challenges.

Metals Australia has successfully produced two commercially viable products from its Manindi Titanium-Vanadium-Iron discovery, while identifying additional promising exploration targets nearby.

Helix Resources has entered conditional agreements to earn up to 40% of the Gold Basin oxide gold project in Arizona, featuring a significant inferred resource and promising metallurgical results.

Marimaca Copper has confirmed significant copper mineralization extending the Pampa Medina Norte discovery, with high-grade oxide and new sulphide zones identified in deep drilling. Assays for deeper intervals are pending, hinting at a potentially large, stacked copper system.

Monadelphous Group Limited has landed a suite of new contracts worth approximately $180 million across Western Australia's resources, energy, and infrastructure sectors, reinforcing its strong foothold in the region.

Fletcher Building is dissolving its Australian Division, folding operations into two new trans-Tasman units, while targeting $15 million in annual cost savings as market challenges persist.

Mayne Pharma Group has proposed a $7.40 per share acquisition by Cosette Pharmaceuticals, with unanimous board support and a fair and reasonable opinion from an independent expert. Shareholders will vote on the scheme on June 18, 2025.

Tempest Minerals reports promising initial metallurgical results from its Remorse Iron discovery in Western Australia, highlighting high-grade iron concentrate with low impurities. Further test results are anticipated, underpinning ongoing project development.

HITIQ Limited has announced a non-renounceable entitlement offer to raise up to $2.92 million, supported by partial underwriting from GBA Capital and accompanied by new options issuance. The capital raise aims to fund expansion, product development, and operational growth.

Bass Limited’s May 2025 AGM update highlights a strategic acquisition and capital raising to accelerate its emergence as a key Australian gas producer, focusing on Cooper Basin and Indonesian assets.

Epsilon Healthcare has launched a $1 million loan note issue aimed at supporting its working capital and diversification efforts, with a 10% interest rate and potential share conversion.

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.